Business Wire

SVANTE/CLIMEWORKS

30.1.2024 16:01:32 CET | Business Wire | Press release

Share
Climeworks and Svante Collaborate in Development and Supply for Direct Air Capture

Climeworks has signed a collaboration and supply agreement with Svante Technologies Inc. (Svante), a leading carbon capture and removal solutions provider. The companies agreed to jointly plan the supply of Svante’s contactor blocks for three major Climeworks projects, intending to lead to a commercial-scale supply agreement, whereby Climeworks would purchase Svante’s contactor blocks for its planned megaton direct air capturing hubs in the US.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130940532/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Claude Letourneau, President & CEO, Svante (Photo: Business Wire)

The US Department of Energy selected Climeworks to develop three of these hubs, in Louisiana, California, and North Dakota, making the company eligible for a total of more than USD 600 million in government funding.

Combined forces for global carbon removal

The collaboration allows both partners to agree on intermediate goals, and to jointly proceed to the next phase of development. “Delivering large-scale direct air capture required us to approach this collaboration with flexibility on the development of project specifications while retaining rigorous accountability for the success of the overall project,” says Claude Letourneau, President and CEO of Svante. “We’ve been closely collaborating with Climeworks over the past three years, and because of that proximity, we felt comfortable entering into this kind of arrangement. The combination of our advanced technologies represents a significant step forward in the nascent direct air capture industry, playing a critical role in meeting the world’s net-zero ambitions.”

Svante is in the final stages of building its commercial filter manufacturing facility, The Centre of Excellence for Carbon Capture and Removal, in Vancouver, BC, Canada. The Centre is equipped to supply both the industrial point source post-combustion carbon capture market and the direct air capture market. Svante has anticipated and prepared for the event where the agreement with Climeworks takes up a significant portion of the Centre’s capacity and has secured additional coating capacity with its partner, 3M.

Best-in-class technology for Climeworks’ large-scale direct air capture projects

With the extended collaboration, Climeworks secures best-in-class technology supporting its scale-up journey. A crucial part of the direct air capture process involves filter material trapping CO2 from the ambient air, and Svante’s filter technology will further enhance the performance of the carbon dioxide capturing process.

“We are focusing on the massive growth of our carbon removal technology to create climate impact,” says Jan Wurzbacher, Co-Founder and Co-CEO of Climeworks. “Svante is one of the key players in the ecosystem to support us in our journey to scale to a gigaton capacity.”

About Svante

Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2024 Global Cleantech 100, the XPRIZE Foundation’s XB100 – World’s Top 100 Deep Tech Companies and was ranked second among private companies in the Corporate Knights’ Future 50 Fastest Growing Sustainable Companies. For more information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/company/svantesolutions.

About Climeworks

Climeworks is the global leader in carbon dioxide removal (CDR) as a service via direct air capture (DAC) technology, empowering companies to advance their net zero roadmaps and fight climate change. Founded by engineers Christoph Gebald and Jan Wurzbacher in 2009, Climeworks is on a journey to climate impact at scale with integrity at its core and a focus on high-quality, permanent carbon removals.

Climeworks is spearheading the DAC industry globally, with the world’s only commercial DAC facility combined with storage installation in operation, modular CO2 collectors designed for scalability, and facilities running on renewable energy. Their growing customer base counts over 160 companies, including multinationals such as Microsoft, BCG, UBS, and Swiss Re.

At Orca, Climeworks’ DAC facility in Iceland, the CO2 is permanently removed from the air by capturing and geologically storing it for thousands of years with Climeworks’ underground mineralization partner Carbfix. The CDR services delivered from Orca are verified by independent 3rd party DNV.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130940532/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye